| 1.61 -0.01 (-0.62%) | 02-11 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.97  |
1-year : | 2.3 |
| Resists | First : | 1.68 |
Second : | 1.97 |
| Pivot price | 1.46 |
|||
| Supports | First : | 1.42 |
Second : | 1.25 |
| MAs | MA(5) : | 1.56 |
MA(20) : | 1.42 |
| MA(100) : | 1.3 |
MA(250) : | 1.41  |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 90.3 |
D(3) : | 87.5 |
| RSI | RSI(14): 67.1 |
|||
| 52-week | High : | 2.83 | Low : | 1.03 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ GERN ] has closed below upper band by 12.3%. Bollinger Bands are 89.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 5 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.69 - 1.7 | 1.7 - 1.71 |
| Low: | 1.54 - 1.55 | 1.55 - 1.56 |
| Close: | 1.6 - 1.61 | 1.61 - 1.62 |
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
Wed, 11 Feb 2026
Geron strategic restructuring plan focuses on Rytelo growth - MSN
Wed, 11 Feb 2026
Geron Corporation to Release Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026 - Quiver Quantitative
Wed, 11 Feb 2026
Geron Plans to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026 - GlobeNewswire
Tue, 10 Feb 2026
Geron (NASDAQ:GERN) Shares Cross Above 200 Day Moving Average - Here's What Happened - MarketBeat
Fri, 06 Feb 2026
Geron Corporation Projects RYTELO Growth Amidst Revised Price Targets - StocksToTrade
Tue, 03 Feb 2026
Geron Corporation's (NASDAQ:GERN) Prospects Need A Boost To Lift Shares - Sahm
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 638 (M) |
| Shares Float | 536 (M) |
| Held by Insiders | 0.1 (%) |
| Held by Institutions | 81 (%) |
| Shares Short | 70,450 (K) |
| Shares Short P.Month | 76,020 (K) |
| EPS | -0.12 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.38 |
| Profit Margin | -43.7 % |
| Operating Margin | -29.5 % |
| Return on Assets (ttm) | -7.8 % |
| Return on Equity (ttm) | -29.6 % |
| Qtrly Rev. Growth | 67 % |
| Gross Profit (p.s.) | 0.15 |
| Sales Per Share | 0.28 |
| EBITDA (p.s.) | -0.1 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -133 (M) |
| Levered Free Cash Flow | -94 (M) |
| PE Ratio | -13.42 |
| PEG Ratio | 0 |
| Price to Book value | 4.12 |
| Price to Sales | 5.6 |
| Price to Cash Flow | -7.74 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|